Client Challenge

Several pharmaceutical companies (from small to large) have proactively started the process of transitioning their 2253 process from paper to electronic in anticipation of the FDA requirements for electronic submissions.

Red Nucleus Solution

The Red Nucleus team utilized their system, clinical, and documentation expertise to develop and execute a plan to deliver the required results. The initial assessment identified gaps in the clinical documentation and associated metadata that needed remediation as well as binders and/or folders that needed to be created and populated. The team developed a plan that included remediation of metadata, creation and population of submission binders/folders, Red Nucleus quality control, and client validation.

Red Nucleus provided recommendations for updates to the metadata, naming conventions, and document versioning and an approach to addressing gaps in the documentation. They established requirements for future alignment/remediation of clinical studies for authority inspections.


Within 5 months, the clinical documentation of the studies for the anticipated FDA inspection were updated in the new document system and submission binders/folders were aligned to match the offcial submission register. Metadata for the documentation were corrected to match the current client standards.